Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure

Mark C. Genovese, Andrea Rubbert-Roth, Josef S. Smolen, Joel Kremer, Majed Khraishi, Juan Gómez-Reino, Anthony Sebba, Robert Pilson, Sarah Williams and Ronald van Vollenhoven
The Journal of Rheumatology March 2013, jrheum.120687; DOI: https://doi.org/10.3899/jrheum.120687
Mark C. Genovese
From the Division of Rheumatology, Stanford University Medical Center, Palo Alto, California, USA; Department of Internal Medicine, University of Cologne, Cologne, Germany; Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Center for Rheumatology, Albany Medical College, State University of New York, Albany, New York, USA; Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador, Canada; Rheumatology Unit Hospital, Clinical Universitario, Santiago, Spain; Department of Rheumatology, University of South Florida, Palm Harbor, Florida, USA; Hoffmann-La Roche Inc., Nutley, New Jersey, USA; PDBB-Biostatistics, Roche Products Limited, Welwyn Garden City, UK; and Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Stockholm, Sweden. Funding for manuscript preparation was provided by F. Hoffmann-La Roche Ltd. Dr. Genovese has received grant support and consulting revenue from Roche. Dr. Rubbert-Roth has received grant support from and has served on the speakers bureau for Roche. Dr. Smolen has received grant support and consulting revenue from and has served on the speakers bureau for Roche. Dr. Kremer has received grant support and consulting revenue from and has served on the speakers bureau for Genentech, a member of the Roche group. Dr. Khraishi has received grant support from Roche Canada and has served on the speakers bureau for Roche. Dr. Gomez-Reino has received research grant support and consulting revenue from Roche. Dr. Sebba has received consulting revenue from and has served on the speakers bureau for Genentech, a member of the Roche group. Dr. Pilson was an employee of Hoffmann-La Roche Inc. Ms. Williams is an employee of Roche Products Ltd. Dr. van Vollenhoven has received grant support, consulting revenue, and honoraria from Roche. M.C. Genovese, MD, Professor, Division of Rheumatology, Stanford University Medical Center; A. Rubbert-Roth, PhD, Professor, Department of Internal Medicine, University of Cologne; J.S. Smolen, MD, Professor, Division of Rheumatology, Department of Medicine III, Medical University of Vienna; J. Kremer, MD, Professor, Center for Rheumatology, Albany Medical College, State University of New York; M. Khraishi, MBBCh, FRCPC, Clinical Professor of Medicine (Rheumatology), Co-chair Human Investigation Committee, Memorial University of Newfoundland; J. Gómez-Reino, MD, Professor of Medicine, Head, Rheumatology Unit, Hospital Clinical Universitario; A. Sebba, MD, Assistant Clinical Professor, Department of Rheumatology, University of South Florida; R. Pilson, MS, Clinical Science Associate, Product Development, Immunology, Hoffmann-La Roche Inc.; S. Williams, MSc, Senior Statistical Scientist, PDBB-Biostatistics, Roche Products Limited; R. van Vollenhoven, MD, PhD, Senior Physician, Associate Professor, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna. Address correspondence to Prof. M.C. Genovese, Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA 94304, USA. E-mail: Genovese@stanford.edu Accepted for publication December 11, 2012.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Rubbert-Roth
From the Division of Rheumatology, Stanford University Medical Center, Palo Alto, California, USA; Department of Internal Medicine, University of Cologne, Cologne, Germany; Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Center for Rheumatology, Albany Medical College, State University of New York, Albany, New York, USA; Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador, Canada; Rheumatology Unit Hospital, Clinical Universitario, Santiago, Spain; Department of Rheumatology, University of South Florida, Palm Harbor, Florida, USA; Hoffmann-La Roche Inc., Nutley, New Jersey, USA; PDBB-Biostatistics, Roche Products Limited, Welwyn Garden City, UK; and Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Stockholm, Sweden. Funding for manuscript preparation was provided by F. Hoffmann-La Roche Ltd. Dr. Genovese has received grant support and consulting revenue from Roche. Dr. Rubbert-Roth has received grant support from and has served on the speakers bureau for Roche. Dr. Smolen has received grant support and consulting revenue from and has served on the speakers bureau for Roche. Dr. Kremer has received grant support and consulting revenue from and has served on the speakers bureau for Genentech, a member of the Roche group. Dr. Khraishi has received grant support from Roche Canada and has served on the speakers bureau for Roche. Dr. Gomez-Reino has received research grant support and consulting revenue from Roche. Dr. Sebba has received consulting revenue from and has served on the speakers bureau for Genentech, a member of the Roche group. Dr. Pilson was an employee of Hoffmann-La Roche Inc. Ms. Williams is an employee of Roche Products Ltd. Dr. van Vollenhoven has received grant support, consulting revenue, and honoraria from Roche. M.C. Genovese, MD, Professor, Division of Rheumatology, Stanford University Medical Center; A. Rubbert-Roth, PhD, Professor, Department of Internal Medicine, University of Cologne; J.S. Smolen, MD, Professor, Division of Rheumatology, Department of Medicine III, Medical University of Vienna; J. Kremer, MD, Professor, Center for Rheumatology, Albany Medical College, State University of New York; M. Khraishi, MBBCh, FRCPC, Clinical Professor of Medicine (Rheumatology), Co-chair Human Investigation Committee, Memorial University of Newfoundland; J. Gómez-Reino, MD, Professor of Medicine, Head, Rheumatology Unit, Hospital Clinical Universitario; A. Sebba, MD, Assistant Clinical Professor, Department of Rheumatology, University of South Florida; R. Pilson, MS, Clinical Science Associate, Product Development, Immunology, Hoffmann-La Roche Inc.; S. Williams, MSc, Senior Statistical Scientist, PDBB-Biostatistics, Roche Products Limited; R. van Vollenhoven, MD, PhD, Senior Physician, Associate Professor, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna. Address correspondence to Prof. M.C. Genovese, Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA 94304, USA. E-mail: Genovese@stanford.edu Accepted for publication December 11, 2012.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josef S. Smolen
From the Division of Rheumatology, Stanford University Medical Center, Palo Alto, California, USA; Department of Internal Medicine, University of Cologne, Cologne, Germany; Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Center for Rheumatology, Albany Medical College, State University of New York, Albany, New York, USA; Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador, Canada; Rheumatology Unit Hospital, Clinical Universitario, Santiago, Spain; Department of Rheumatology, University of South Florida, Palm Harbor, Florida, USA; Hoffmann-La Roche Inc., Nutley, New Jersey, USA; PDBB-Biostatistics, Roche Products Limited, Welwyn Garden City, UK; and Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Stockholm, Sweden. Funding for manuscript preparation was provided by F. Hoffmann-La Roche Ltd. Dr. Genovese has received grant support and consulting revenue from Roche. Dr. Rubbert-Roth has received grant support from and has served on the speakers bureau for Roche. Dr. Smolen has received grant support and consulting revenue from and has served on the speakers bureau for Roche. Dr. Kremer has received grant support and consulting revenue from and has served on the speakers bureau for Genentech, a member of the Roche group. Dr. Khraishi has received grant support from Roche Canada and has served on the speakers bureau for Roche. Dr. Gomez-Reino has received research grant support and consulting revenue from Roche. Dr. Sebba has received consulting revenue from and has served on the speakers bureau for Genentech, a member of the Roche group. Dr. Pilson was an employee of Hoffmann-La Roche Inc. Ms. Williams is an employee of Roche Products Ltd. Dr. van Vollenhoven has received grant support, consulting revenue, and honoraria from Roche. M.C. Genovese, MD, Professor, Division of Rheumatology, Stanford University Medical Center; A. Rubbert-Roth, PhD, Professor, Department of Internal Medicine, University of Cologne; J.S. Smolen, MD, Professor, Division of Rheumatology, Department of Medicine III, Medical University of Vienna; J. Kremer, MD, Professor, Center for Rheumatology, Albany Medical College, State University of New York; M. Khraishi, MBBCh, FRCPC, Clinical Professor of Medicine (Rheumatology), Co-chair Human Investigation Committee, Memorial University of Newfoundland; J. Gómez-Reino, MD, Professor of Medicine, Head, Rheumatology Unit, Hospital Clinical Universitario; A. Sebba, MD, Assistant Clinical Professor, Department of Rheumatology, University of South Florida; R. Pilson, MS, Clinical Science Associate, Product Development, Immunology, Hoffmann-La Roche Inc.; S. Williams, MSc, Senior Statistical Scientist, PDBB-Biostatistics, Roche Products Limited; R. van Vollenhoven, MD, PhD, Senior Physician, Associate Professor, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna. Address correspondence to Prof. M.C. Genovese, Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA 94304, USA. E-mail: Genovese@stanford.edu Accepted for publication December 11, 2012.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel Kremer
From the Division of Rheumatology, Stanford University Medical Center, Palo Alto, California, USA; Department of Internal Medicine, University of Cologne, Cologne, Germany; Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Center for Rheumatology, Albany Medical College, State University of New York, Albany, New York, USA; Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador, Canada; Rheumatology Unit Hospital, Clinical Universitario, Santiago, Spain; Department of Rheumatology, University of South Florida, Palm Harbor, Florida, USA; Hoffmann-La Roche Inc., Nutley, New Jersey, USA; PDBB-Biostatistics, Roche Products Limited, Welwyn Garden City, UK; and Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Stockholm, Sweden. Funding for manuscript preparation was provided by F. Hoffmann-La Roche Ltd. Dr. Genovese has received grant support and consulting revenue from Roche. Dr. Rubbert-Roth has received grant support from and has served on the speakers bureau for Roche. Dr. Smolen has received grant support and consulting revenue from and has served on the speakers bureau for Roche. Dr. Kremer has received grant support and consulting revenue from and has served on the speakers bureau for Genentech, a member of the Roche group. Dr. Khraishi has received grant support from Roche Canada and has served on the speakers bureau for Roche. Dr. Gomez-Reino has received research grant support and consulting revenue from Roche. Dr. Sebba has received consulting revenue from and has served on the speakers bureau for Genentech, a member of the Roche group. Dr. Pilson was an employee of Hoffmann-La Roche Inc. Ms. Williams is an employee of Roche Products Ltd. Dr. van Vollenhoven has received grant support, consulting revenue, and honoraria from Roche. M.C. Genovese, MD, Professor, Division of Rheumatology, Stanford University Medical Center; A. Rubbert-Roth, PhD, Professor, Department of Internal Medicine, University of Cologne; J.S. Smolen, MD, Professor, Division of Rheumatology, Department of Medicine III, Medical University of Vienna; J. Kremer, MD, Professor, Center for Rheumatology, Albany Medical College, State University of New York; M. Khraishi, MBBCh, FRCPC, Clinical Professor of Medicine (Rheumatology), Co-chair Human Investigation Committee, Memorial University of Newfoundland; J. Gómez-Reino, MD, Professor of Medicine, Head, Rheumatology Unit, Hospital Clinical Universitario; A. Sebba, MD, Assistant Clinical Professor, Department of Rheumatology, University of South Florida; R. Pilson, MS, Clinical Science Associate, Product Development, Immunology, Hoffmann-La Roche Inc.; S. Williams, MSc, Senior Statistical Scientist, PDBB-Biostatistics, Roche Products Limited; R. van Vollenhoven, MD, PhD, Senior Physician, Associate Professor, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna. Address correspondence to Prof. M.C. Genovese, Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA 94304, USA. E-mail: Genovese@stanford.edu Accepted for publication December 11, 2012.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Majed Khraishi
From the Division of Rheumatology, Stanford University Medical Center, Palo Alto, California, USA; Department of Internal Medicine, University of Cologne, Cologne, Germany; Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Center for Rheumatology, Albany Medical College, State University of New York, Albany, New York, USA; Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador, Canada; Rheumatology Unit Hospital, Clinical Universitario, Santiago, Spain; Department of Rheumatology, University of South Florida, Palm Harbor, Florida, USA; Hoffmann-La Roche Inc., Nutley, New Jersey, USA; PDBB-Biostatistics, Roche Products Limited, Welwyn Garden City, UK; and Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Stockholm, Sweden. Funding for manuscript preparation was provided by F. Hoffmann-La Roche Ltd. Dr. Genovese has received grant support and consulting revenue from Roche. Dr. Rubbert-Roth has received grant support from and has served on the speakers bureau for Roche. Dr. Smolen has received grant support and consulting revenue from and has served on the speakers bureau for Roche. Dr. Kremer has received grant support and consulting revenue from and has served on the speakers bureau for Genentech, a member of the Roche group. Dr. Khraishi has received grant support from Roche Canada and has served on the speakers bureau for Roche. Dr. Gomez-Reino has received research grant support and consulting revenue from Roche. Dr. Sebba has received consulting revenue from and has served on the speakers bureau for Genentech, a member of the Roche group. Dr. Pilson was an employee of Hoffmann-La Roche Inc. Ms. Williams is an employee of Roche Products Ltd. Dr. van Vollenhoven has received grant support, consulting revenue, and honoraria from Roche. M.C. Genovese, MD, Professor, Division of Rheumatology, Stanford University Medical Center; A. Rubbert-Roth, PhD, Professor, Department of Internal Medicine, University of Cologne; J.S. Smolen, MD, Professor, Division of Rheumatology, Department of Medicine III, Medical University of Vienna; J. Kremer, MD, Professor, Center for Rheumatology, Albany Medical College, State University of New York; M. Khraishi, MBBCh, FRCPC, Clinical Professor of Medicine (Rheumatology), Co-chair Human Investigation Committee, Memorial University of Newfoundland; J. Gómez-Reino, MD, Professor of Medicine, Head, Rheumatology Unit, Hospital Clinical Universitario; A. Sebba, MD, Assistant Clinical Professor, Department of Rheumatology, University of South Florida; R. Pilson, MS, Clinical Science Associate, Product Development, Immunology, Hoffmann-La Roche Inc.; S. Williams, MSc, Senior Statistical Scientist, PDBB-Biostatistics, Roche Products Limited; R. van Vollenhoven, MD, PhD, Senior Physician, Associate Professor, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna. Address correspondence to Prof. M.C. Genovese, Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA 94304, USA. E-mail: Genovese@stanford.edu Accepted for publication December 11, 2012.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan Gómez-Reino
From the Division of Rheumatology, Stanford University Medical Center, Palo Alto, California, USA; Department of Internal Medicine, University of Cologne, Cologne, Germany; Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Center for Rheumatology, Albany Medical College, State University of New York, Albany, New York, USA; Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador, Canada; Rheumatology Unit Hospital, Clinical Universitario, Santiago, Spain; Department of Rheumatology, University of South Florida, Palm Harbor, Florida, USA; Hoffmann-La Roche Inc., Nutley, New Jersey, USA; PDBB-Biostatistics, Roche Products Limited, Welwyn Garden City, UK; and Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Stockholm, Sweden. Funding for manuscript preparation was provided by F. Hoffmann-La Roche Ltd. Dr. Genovese has received grant support and consulting revenue from Roche. Dr. Rubbert-Roth has received grant support from and has served on the speakers bureau for Roche. Dr. Smolen has received grant support and consulting revenue from and has served on the speakers bureau for Roche. Dr. Kremer has received grant support and consulting revenue from and has served on the speakers bureau for Genentech, a member of the Roche group. Dr. Khraishi has received grant support from Roche Canada and has served on the speakers bureau for Roche. Dr. Gomez-Reino has received research grant support and consulting revenue from Roche. Dr. Sebba has received consulting revenue from and has served on the speakers bureau for Genentech, a member of the Roche group. Dr. Pilson was an employee of Hoffmann-La Roche Inc. Ms. Williams is an employee of Roche Products Ltd. Dr. van Vollenhoven has received grant support, consulting revenue, and honoraria from Roche. M.C. Genovese, MD, Professor, Division of Rheumatology, Stanford University Medical Center; A. Rubbert-Roth, PhD, Professor, Department of Internal Medicine, University of Cologne; J.S. Smolen, MD, Professor, Division of Rheumatology, Department of Medicine III, Medical University of Vienna; J. Kremer, MD, Professor, Center for Rheumatology, Albany Medical College, State University of New York; M. Khraishi, MBBCh, FRCPC, Clinical Professor of Medicine (Rheumatology), Co-chair Human Investigation Committee, Memorial University of Newfoundland; J. Gómez-Reino, MD, Professor of Medicine, Head, Rheumatology Unit, Hospital Clinical Universitario; A. Sebba, MD, Assistant Clinical Professor, Department of Rheumatology, University of South Florida; R. Pilson, MS, Clinical Science Associate, Product Development, Immunology, Hoffmann-La Roche Inc.; S. Williams, MSc, Senior Statistical Scientist, PDBB-Biostatistics, Roche Products Limited; R. van Vollenhoven, MD, PhD, Senior Physician, Associate Professor, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna. Address correspondence to Prof. M.C. Genovese, Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA 94304, USA. E-mail: Genovese@stanford.edu Accepted for publication December 11, 2012.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Sebba
From the Division of Rheumatology, Stanford University Medical Center, Palo Alto, California, USA; Department of Internal Medicine, University of Cologne, Cologne, Germany; Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Center for Rheumatology, Albany Medical College, State University of New York, Albany, New York, USA; Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador, Canada; Rheumatology Unit Hospital, Clinical Universitario, Santiago, Spain; Department of Rheumatology, University of South Florida, Palm Harbor, Florida, USA; Hoffmann-La Roche Inc., Nutley, New Jersey, USA; PDBB-Biostatistics, Roche Products Limited, Welwyn Garden City, UK; and Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Stockholm, Sweden. Funding for manuscript preparation was provided by F. Hoffmann-La Roche Ltd. Dr. Genovese has received grant support and consulting revenue from Roche. Dr. Rubbert-Roth has received grant support from and has served on the speakers bureau for Roche. Dr. Smolen has received grant support and consulting revenue from and has served on the speakers bureau for Roche. Dr. Kremer has received grant support and consulting revenue from and has served on the speakers bureau for Genentech, a member of the Roche group. Dr. Khraishi has received grant support from Roche Canada and has served on the speakers bureau for Roche. Dr. Gomez-Reino has received research grant support and consulting revenue from Roche. Dr. Sebba has received consulting revenue from and has served on the speakers bureau for Genentech, a member of the Roche group. Dr. Pilson was an employee of Hoffmann-La Roche Inc. Ms. Williams is an employee of Roche Products Ltd. Dr. van Vollenhoven has received grant support, consulting revenue, and honoraria from Roche. M.C. Genovese, MD, Professor, Division of Rheumatology, Stanford University Medical Center; A. Rubbert-Roth, PhD, Professor, Department of Internal Medicine, University of Cologne; J.S. Smolen, MD, Professor, Division of Rheumatology, Department of Medicine III, Medical University of Vienna; J. Kremer, MD, Professor, Center for Rheumatology, Albany Medical College, State University of New York; M. Khraishi, MBBCh, FRCPC, Clinical Professor of Medicine (Rheumatology), Co-chair Human Investigation Committee, Memorial University of Newfoundland; J. Gómez-Reino, MD, Professor of Medicine, Head, Rheumatology Unit, Hospital Clinical Universitario; A. Sebba, MD, Assistant Clinical Professor, Department of Rheumatology, University of South Florida; R. Pilson, MS, Clinical Science Associate, Product Development, Immunology, Hoffmann-La Roche Inc.; S. Williams, MSc, Senior Statistical Scientist, PDBB-Biostatistics, Roche Products Limited; R. van Vollenhoven, MD, PhD, Senior Physician, Associate Professor, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna. Address correspondence to Prof. M.C. Genovese, Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA 94304, USA. E-mail: Genovese@stanford.edu Accepted for publication December 11, 2012.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Pilson
From the Division of Rheumatology, Stanford University Medical Center, Palo Alto, California, USA; Department of Internal Medicine, University of Cologne, Cologne, Germany; Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Center for Rheumatology, Albany Medical College, State University of New York, Albany, New York, USA; Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador, Canada; Rheumatology Unit Hospital, Clinical Universitario, Santiago, Spain; Department of Rheumatology, University of South Florida, Palm Harbor, Florida, USA; Hoffmann-La Roche Inc., Nutley, New Jersey, USA; PDBB-Biostatistics, Roche Products Limited, Welwyn Garden City, UK; and Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Stockholm, Sweden. Funding for manuscript preparation was provided by F. Hoffmann-La Roche Ltd. Dr. Genovese has received grant support and consulting revenue from Roche. Dr. Rubbert-Roth has received grant support from and has served on the speakers bureau for Roche. Dr. Smolen has received grant support and consulting revenue from and has served on the speakers bureau for Roche. Dr. Kremer has received grant support and consulting revenue from and has served on the speakers bureau for Genentech, a member of the Roche group. Dr. Khraishi has received grant support from Roche Canada and has served on the speakers bureau for Roche. Dr. Gomez-Reino has received research grant support and consulting revenue from Roche. Dr. Sebba has received consulting revenue from and has served on the speakers bureau for Genentech, a member of the Roche group. Dr. Pilson was an employee of Hoffmann-La Roche Inc. Ms. Williams is an employee of Roche Products Ltd. Dr. van Vollenhoven has received grant support, consulting revenue, and honoraria from Roche. M.C. Genovese, MD, Professor, Division of Rheumatology, Stanford University Medical Center; A. Rubbert-Roth, PhD, Professor, Department of Internal Medicine, University of Cologne; J.S. Smolen, MD, Professor, Division of Rheumatology, Department of Medicine III, Medical University of Vienna; J. Kremer, MD, Professor, Center for Rheumatology, Albany Medical College, State University of New York; M. Khraishi, MBBCh, FRCPC, Clinical Professor of Medicine (Rheumatology), Co-chair Human Investigation Committee, Memorial University of Newfoundland; J. Gómez-Reino, MD, Professor of Medicine, Head, Rheumatology Unit, Hospital Clinical Universitario; A. Sebba, MD, Assistant Clinical Professor, Department of Rheumatology, University of South Florida; R. Pilson, MS, Clinical Science Associate, Product Development, Immunology, Hoffmann-La Roche Inc.; S. Williams, MSc, Senior Statistical Scientist, PDBB-Biostatistics, Roche Products Limited; R. van Vollenhoven, MD, PhD, Senior Physician, Associate Professor, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna. Address correspondence to Prof. M.C. Genovese, Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA 94304, USA. E-mail: Genovese@stanford.edu Accepted for publication December 11, 2012.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Williams
From the Division of Rheumatology, Stanford University Medical Center, Palo Alto, California, USA; Department of Internal Medicine, University of Cologne, Cologne, Germany; Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Center for Rheumatology, Albany Medical College, State University of New York, Albany, New York, USA; Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador, Canada; Rheumatology Unit Hospital, Clinical Universitario, Santiago, Spain; Department of Rheumatology, University of South Florida, Palm Harbor, Florida, USA; Hoffmann-La Roche Inc., Nutley, New Jersey, USA; PDBB-Biostatistics, Roche Products Limited, Welwyn Garden City, UK; and Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Stockholm, Sweden. Funding for manuscript preparation was provided by F. Hoffmann-La Roche Ltd. Dr. Genovese has received grant support and consulting revenue from Roche. Dr. Rubbert-Roth has received grant support from and has served on the speakers bureau for Roche. Dr. Smolen has received grant support and consulting revenue from and has served on the speakers bureau for Roche. Dr. Kremer has received grant support and consulting revenue from and has served on the speakers bureau for Genentech, a member of the Roche group. Dr. Khraishi has received grant support from Roche Canada and has served on the speakers bureau for Roche. Dr. Gomez-Reino has received research grant support and consulting revenue from Roche. Dr. Sebba has received consulting revenue from and has served on the speakers bureau for Genentech, a member of the Roche group. Dr. Pilson was an employee of Hoffmann-La Roche Inc. Ms. Williams is an employee of Roche Products Ltd. Dr. van Vollenhoven has received grant support, consulting revenue, and honoraria from Roche. M.C. Genovese, MD, Professor, Division of Rheumatology, Stanford University Medical Center; A. Rubbert-Roth, PhD, Professor, Department of Internal Medicine, University of Cologne; J.S. Smolen, MD, Professor, Division of Rheumatology, Department of Medicine III, Medical University of Vienna; J. Kremer, MD, Professor, Center for Rheumatology, Albany Medical College, State University of New York; M. Khraishi, MBBCh, FRCPC, Clinical Professor of Medicine (Rheumatology), Co-chair Human Investigation Committee, Memorial University of Newfoundland; J. Gómez-Reino, MD, Professor of Medicine, Head, Rheumatology Unit, Hospital Clinical Universitario; A. Sebba, MD, Assistant Clinical Professor, Department of Rheumatology, University of South Florida; R. Pilson, MS, Clinical Science Associate, Product Development, Immunology, Hoffmann-La Roche Inc.; S. Williams, MSc, Senior Statistical Scientist, PDBB-Biostatistics, Roche Products Limited; R. van Vollenhoven, MD, PhD, Senior Physician, Associate Professor, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna. Address correspondence to Prof. M.C. Genovese, Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA 94304, USA. E-mail: Genovese@stanford.edu Accepted for publication December 11, 2012.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald van Vollenhoven
From the Division of Rheumatology, Stanford University Medical Center, Palo Alto, California, USA; Department of Internal Medicine, University of Cologne, Cologne, Germany; Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Center for Rheumatology, Albany Medical College, State University of New York, Albany, New York, USA; Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador, Canada; Rheumatology Unit Hospital, Clinical Universitario, Santiago, Spain; Department of Rheumatology, University of South Florida, Palm Harbor, Florida, USA; Hoffmann-La Roche Inc., Nutley, New Jersey, USA; PDBB-Biostatistics, Roche Products Limited, Welwyn Garden City, UK; and Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Stockholm, Sweden. Funding for manuscript preparation was provided by F. Hoffmann-La Roche Ltd. Dr. Genovese has received grant support and consulting revenue from Roche. Dr. Rubbert-Roth has received grant support from and has served on the speakers bureau for Roche. Dr. Smolen has received grant support and consulting revenue from and has served on the speakers bureau for Roche. Dr. Kremer has received grant support and consulting revenue from and has served on the speakers bureau for Genentech, a member of the Roche group. Dr. Khraishi has received grant support from Roche Canada and has served on the speakers bureau for Roche. Dr. Gomez-Reino has received research grant support and consulting revenue from Roche. Dr. Sebba has received consulting revenue from and has served on the speakers bureau for Genentech, a member of the Roche group. Dr. Pilson was an employee of Hoffmann-La Roche Inc. Ms. Williams is an employee of Roche Products Ltd. Dr. van Vollenhoven has received grant support, consulting revenue, and honoraria from Roche. M.C. Genovese, MD, Professor, Division of Rheumatology, Stanford University Medical Center; A. Rubbert-Roth, PhD, Professor, Department of Internal Medicine, University of Cologne; J.S. Smolen, MD, Professor, Division of Rheumatology, Department of Medicine III, Medical University of Vienna; J. Kremer, MD, Professor, Center for Rheumatology, Albany Medical College, State University of New York; M. Khraishi, MBBCh, FRCPC, Clinical Professor of Medicine (Rheumatology), Co-chair Human Investigation Committee, Memorial University of Newfoundland; J. Gómez-Reino, MD, Professor of Medicine, Head, Rheumatology Unit, Hospital Clinical Universitario; A. Sebba, MD, Assistant Clinical Professor, Department of Rheumatology, University of South Florida; R. Pilson, MS, Clinical Science Associate, Product Development, Immunology, Hoffmann-La Roche Inc.; S. Williams, MSc, Senior Statistical Scientist, PDBB-Biostatistics, Roche Products Limited; R. van Vollenhoven, MD, PhD, Senior Physician, Associate Professor, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna. Address correspondence to Prof. M.C. Genovese, Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA 94304, USA. E-mail: Genovese@stanford.edu Accepted for publication December 11, 2012.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • References
  • PDF
Next
Loading

Abstract

Objective To assess the longterm safety and efficacy of tocilizumab (TCZ) in patients with moderate to severe rheumatoid arthritis (RA).

Methods Patient data were from 5 randomized controlled TCZ trials (n = 4211), their open-label extension phases (n = 3512), and a drug interaction study (n = 23). All randomly assigned patients, regardless of previous RA treatment, were analyzed. Measures of safety included number of adverse events (AE), serious AE (SAE), AE leading to treatment discontinuation, laboratory tests, and deaths. Efficacy measures included American College of Rheumatology (ACR) 20/50/70 responses, tender joint count (TJC), swollen joint count (SJC), ACR core set components, and low disease activity (LDA) or Disease Activity Score in 28 joints (DAS28) remission. ACR/European League Against Rheumatism (EULAR) disease remission was a posthoc exploratory analysis.

Results Total duration of observation was 12,293 patient-years (PY). No new safety signals were identified; infections were the most common AE and SAE. The rate of serious infections was 4.5/100 PY. Improvements from baseline in clinical efficacy, measured as ACR20/50/70 responses, TJC, SJC, ACR core set components, and LDA and DAS28 remission, were generally sustained through at least 216 weeks of followup. ACR/EULAR disease remission was attained by 16.5% (Boolean) and 22.7% (index) of patients at Week 216.

Conclusion TCZ has to date been studied for up to 4.6 years (240 weeks) of treatment in patients with RA. Our analysis reveals a longer-term safety profile consistent with previous observations, no new safety signals, and durable efficacy of TCZ in a large clinical trial program.

Next
Back to top

In this issue

The Journal of Rheumatology
Vol. 52, Issue 6
1 Jun 2025
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
Mark C. Genovese, Andrea Rubbert-Roth, Josef S. Smolen, Joel Kremer, Majed Khraishi, Juan Gómez-Reino, Anthony Sebba, Robert Pilson, Sarah Williams, Ronald van Vollenhoven
The Journal of Rheumatology Mar 2013, jrheum.120687; DOI: 10.3899/jrheum.120687

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
Mark C. Genovese, Andrea Rubbert-Roth, Josef S. Smolen, Joel Kremer, Majed Khraishi, Juan Gómez-Reino, Anthony Sebba, Robert Pilson, Sarah Williams, Ronald van Vollenhoven
The Journal of Rheumatology Mar 2013, jrheum.120687; DOI: 10.3899/jrheum.120687
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Understanding the Psoriasis Phenotype Associated With Psoriatic Arthritis Using the PURE-4 Questionnaire: Insights From Spanish Real-World Settings
  • HLA-B27 Testing in Clinical Practice: A Retrospective Analysis of Testing Indications and Rheumatology Referral Patterns
  • Analysis of Gut-Homing Receptors in Circulating Mucosal-Associated Invariant T Cells and Their Presence in Synovial Tissue From Patients With Axial Spondyloarthritis
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire